MX2024005654A - Análogos de la proteína de fusión de la relaxina-2 y métodos de usos de los mismos. - Google Patents
Análogos de la proteína de fusión de la relaxina-2 y métodos de usos de los mismos.Info
- Publication number
- MX2024005654A MX2024005654A MX2024005654A MX2024005654A MX2024005654A MX 2024005654 A MX2024005654 A MX 2024005654A MX 2024005654 A MX2024005654 A MX 2024005654A MX 2024005654 A MX2024005654 A MX 2024005654A MX 2024005654 A MX2024005654 A MX 2024005654A
- Authority
- MX
- Mexico
- Prior art keywords
- relaxin
- methods
- fusion protein
- life
- protein analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263917P | 2021-11-11 | 2021-11-11 | |
| PCT/US2022/079681 WO2023086913A2 (en) | 2021-11-11 | 2022-11-11 | Relaxin-2 fusion protein analogs and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005654A true MX2024005654A (es) | 2024-09-11 |
Family
ID=86336636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005654A MX2024005654A (es) | 2021-11-11 | 2022-11-11 | Análogos de la proteína de fusión de la relaxina-2 y métodos de usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12509497B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4429694A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024543455A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240110824A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118510536A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022388751A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3237801A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312731A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005654A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023086913A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023086913A2 (en) | 2021-11-11 | 2023-05-19 | Tectonic Therapeutic, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
| EP4713001A2 (en) | 2023-05-18 | 2026-03-25 | Tectonic Operating Company, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4835251A (en) | 1986-06-23 | 1989-05-30 | Genetech, Inc. | Method of chain combination |
| WO2007115414A1 (en) | 2006-04-11 | 2007-10-18 | University Of Guelph | Modified h2 relaxin for tumor suppression |
| CA2704246A1 (en) | 2007-10-30 | 2009-05-07 | Howard Florey Institute Of Experimental Physiology And Medicine | Chimeric relaxin polypeptides comprising an a and b chain derived from different relaxin family peptides |
| WO2010105081A1 (en) | 2009-03-13 | 2010-09-16 | Medtronic, Inc. | Method of treating heart failure |
| US8389475B2 (en) | 2009-08-10 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Relaxin analogs |
| US20110245469A1 (en) | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives |
| PE20140160A1 (es) | 2010-08-17 | 2014-02-08 | Ambrx Inc | Polipeptidos de relaxina modificados y sus usos |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| WO2012031327A1 (en) | 2010-09-08 | 2012-03-15 | Howard Florey Institute Of Experimental Physiology And Medicine | Modified relaxin polypeptides |
| GB201110833D0 (en) | 2011-06-24 | 2011-08-10 | Bold Venture Llc | Compositions |
| AU2012280474A1 (en) | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| AU2012283235A1 (en) | 2011-07-08 | 2014-01-09 | Bayer Intellectual Property Gmbh | Fusion proteins releasing Relaxin and uses thereof |
| AU2012291972B2 (en) | 2011-08-04 | 2017-03-09 | Pharis Biotec Gmbh | Process for preparing human relaxin-2 |
| EP2630964A1 (en) | 2012-02-22 | 2013-08-28 | Immundiagnostik AG | Method and medicament for treating patients in risk of prediabetes and type-2 diabetes |
| WO2013177529A1 (en) | 2012-05-24 | 2013-11-28 | Angion Biomedica Corp. | Relaxin-like compounds and uses thereof |
| US20160060322A1 (en) | 2012-09-10 | 2016-03-03 | Angion Biomedica Corp. | Relaxin-like peptides and uses thereof |
| US9381231B2 (en) | 2012-10-09 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies |
| US20150232526A1 (en) | 2012-10-10 | 2015-08-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of relaxin to treat atrial fibrillation |
| US9005630B2 (en) | 2012-11-01 | 2015-04-14 | Veterinaerinstituttet | Fusion proteins for the treatment of allergic diseases |
| US9907833B2 (en) | 2013-07-25 | 2018-03-06 | University Of Florida Research Foundation, Incorporated | Use of relaxin to treat placental syndromes |
| WO2015038938A1 (en) | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| JP6694381B2 (ja) | 2013-09-24 | 2020-05-13 | エラスタジェン・プロプライエタリー・リミテッドElastagen Pty Ltd | タンパク質抽出方法 |
| WO2015073727A1 (en) | 2013-11-13 | 2015-05-21 | Aequus Biopharma, Inc. | Engineered glycoproteins and uses thereof |
| EP3083977B1 (en) * | 2013-12-20 | 2018-02-28 | F. Hoffmann-La Roche AG | Improved recombinant polypeptide production methods |
| CA2945838C (en) | 2014-04-17 | 2022-08-16 | The Florey Institute Of Neuroscience And Mental Health | Modified relaxin b chain peptides |
| EP2946788A1 (en) | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
| WO2016144968A1 (en) | 2015-03-09 | 2016-09-15 | University Of Washington | Relaxin therapy for disorders of the diaphragm |
| GB201516068D0 (en) | 2015-09-10 | 2015-10-28 | Biomed Ltd B V | Novel therapy |
| US11161891B2 (en) | 2015-12-09 | 2021-11-02 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
| CN115837014A (zh) | 2016-05-18 | 2023-03-24 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
| US20190307811A1 (en) | 2016-08-04 | 2019-10-10 | Hudson Institute of Medical Research | Method for treating airways disease |
| EP3522911B1 (en) | 2016-10-07 | 2021-12-08 | Beth Israel Deaconess Medical Center, Inc. | Compositions comprising relaxin and methods of use thereof |
| WO2018138170A1 (en) * | 2017-01-25 | 2018-08-02 | Medimmune, Llc | Relaxin fusion polypeptides and uses thereof |
| SG10201912034UA (en) | 2017-02-08 | 2020-02-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| TW201934572A (zh) | 2018-01-31 | 2019-09-01 | 法商賽諾菲公司 | 經修飾之鬆弛素b鏈胜肽及其治療用途 |
| MY199821A (en) | 2018-01-31 | 2023-11-23 | Sanofi Sa | Modified lipidated relaxin b chain peptides and their therapeutic use |
| WO2019149781A1 (en) | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| EP4058048A1 (en) | 2019-11-16 | 2022-09-21 | Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | Medical composition for treating cardiac wasting and cachexia |
| JP2023524981A (ja) * | 2020-05-08 | 2023-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 操作されたリラキシンおよびその使用の方法 |
| EP4153214A4 (en) | 2020-05-22 | 2024-06-26 | Trustees of Boston University | Methods and compositions for treating a fibrotic disease |
| WO2021247475A1 (en) | 2020-06-02 | 2021-12-09 | Trustees Of Boston University | Production of soluble relaxin and relaxin analogs |
| CR20230015A (es) | 2020-06-17 | 2023-02-17 | Medimmune Ltd | Fusiones heterodiméricas de relaxina y usos de las mismas |
| CN114075276A (zh) | 2020-08-17 | 2022-02-22 | 成都奥达生物科技有限公司 | 一种长效松弛素2类似物 |
| CN113577289A (zh) | 2021-01-11 | 2021-11-02 | 张莉 | Rxfp1/3抑制剂在制备预防或治疗青少年特发性脊柱侧凸疾病的药物中的用途 |
| WO2023028008A2 (en) | 2021-08-23 | 2023-03-02 | River 2 Renal Corp. | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions |
| EP4402474A1 (en) | 2021-09-14 | 2024-07-24 | Bellylabs OY | Assay method for relaxin |
| US20250017867A1 (en) | 2021-10-01 | 2025-01-16 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| WO2023086913A2 (en) | 2021-11-11 | 2023-05-19 | Tectonic Therapeutic, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
| JP2024546877A (ja) | 2021-12-15 | 2024-12-26 | メドイミューン・リミテッド | ヘテロ二量体リラキシン融合物を使用した治療 |
| JP2025517100A (ja) | 2022-05-07 | 2025-06-03 | 北京拓界生物医薬科技有限公司 | リラキシン又は類似体の融合タンパク質及びその医薬的使用 |
| JP2025528469A (ja) | 2022-08-31 | 2025-08-28 | リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー. カーゲー | 免疫抑制薬及び処置方法 |
| EP4713001A2 (en) * | 2023-05-18 | 2026-03-25 | Tectonic Operating Company, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
-
2022
- 2022-11-11 WO PCT/US2022/079681 patent/WO2023086913A2/en not_active Ceased
- 2022-11-11 KR KR1020247019339A patent/KR20240110824A/ko active Pending
- 2022-11-11 AU AU2022388751A patent/AU2022388751A1/en active Pending
- 2022-11-11 MX MX2024005654A patent/MX2024005654A/es unknown
- 2022-11-11 US US18/054,596 patent/US12509497B2/en active Active
- 2022-11-11 EP EP22893856.9A patent/EP4429694A4/en active Pending
- 2022-11-11 CN CN202280086174.7A patent/CN118510536A/zh active Pending
- 2022-11-11 JP JP2024527767A patent/JP2024543455A/ja active Pending
- 2022-11-11 CA CA3237801A patent/CA3237801A1/en active Pending
- 2022-11-11 IL IL312731A patent/IL312731A/en unknown
-
2025
- 2025-11-21 US US19/397,507 patent/US20260234213A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118510536A (zh) | 2024-08-16 |
| US20230340058A1 (en) | 2023-10-26 |
| KR20240110824A (ko) | 2024-07-16 |
| EP4429694A2 (en) | 2024-09-18 |
| JP2024543455A (ja) | 2024-11-21 |
| EP4429694A4 (en) | 2025-10-01 |
| AU2022388751A1 (en) | 2024-05-30 |
| IL312731A (en) | 2024-07-01 |
| US20260234213A1 (en) | 2026-08-13 |
| CA3237801A1 (en) | 2023-05-19 |
| WO2023086913A3 (en) | 2023-06-22 |
| WO2023086913A2 (en) | 2023-05-19 |
| US12509497B2 (en) | 2025-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2982752T3 (es) | Composiciones farmacéuticas de il-2 | |
| DE3784905T2 (de) | Gamma-l-glutamyl-l-cysteinethylester und arzneimittel, die dieses als aktives mittel enthalten. | |
| WO2023086913A3 (en) | Relaxin-2 fusion protein analogs and methods of using same | |
| RU2012134974A (ru) | Стабилизированное соединение гормона роста | |
| US20230144955A1 (en) | Peptide for preventing or treating hair loss, and use thereof | |
| US9279004B2 (en) | Synthetic PnTx(19) peptide, pharmaceutical compositions and use | |
| US20180265549A1 (en) | Cyclic polypeptides, method for obtaining them and the therapeutic use thereof | |
| RU2011133926A (ru) | Стабилизированные гормоны роста | |
| EA021186B1 (ru) | Композиции, включающие интерлейкин-1 и пептиды | |
| JPS60184011A (ja) | 免疫調節剤 | |
| JPH02117698A (ja) | 血管内皮細胞成長因子 | |
| WO2007048353B1 (en) | Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases | |
| MX2025006410A (es) | Fexamétodos para tratar la enfermedad de pompe de inicio infantil en pacientes pediátricos | |
| EP4699613A1 (en) | Novel use of cpne7 protein-derived peptide | |
| CN104524544B (zh) | 一种多肽在治疗糖尿病中的应用 | |
| CN105232577A (zh) | 一种脂肪来源干细胞因子的生发技术 | |
| KR20200044434A (ko) | 물질 p를 포함하는 난치성 궤양 치료용 조성물 | |
| KR20120136306A (ko) | 속눈썹 성장용 조성물 | |
| EP2219663B1 (de) | Reverses protein | |
| TWI792375B (zh) | 乳鐵蛋白的衍生胜肽及其促進及/或增加油脂生成的用途 | |
| EP4353246A1 (en) | Use of bletilla formosana (hayata) schltr. extract for the manufacture of a pharmaceutical composition for promoting chronic wound healing | |
| KR20120022293A (ko) | 산양산삼 추출물을 함유한 혈관주입용 약제학적 조성물 | |
| CN112972449A (zh) | 一种安全性高的药物组合物及其制备方法 | |
| US20190099466A1 (en) | Peptide for promoting wound healing, its composition and method of using the same | |
| RU2002113429A (ru) | Способ лечения псориаза |